Candel Therapeutics (NASDAQ: $CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 from all inc hpx bangla ¦ Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 11:6 👁 View: 420K times ✓ Published: 03-Jun-2024
Description: Clinical-stage biopharmaceutical company Candel Therapeutics, Inc., reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.